Biogen says it expects revenue to fall in 2026 as its multiple sclerosis therapies continue to struggle.

Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new ...

Feb 6 (Reuters) - Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines ...

US biotech major Biogen (Nasdaq: BIIB) has elected Maria Freire as chair of the board of directors. She will take up the role ...

Biogen (BIIB) stock gains as the company beats estimates for Q4 2025 despite projecting a revenue decline for 2026. Read more ...

Biogen is transitioning from a shrinking MS franchise to a portfolio anchored in rare disease and Alzheimer’s therapies, ...

Biogen (NASDAQ:BIIB) executives said the company ended 2025 “slightly above the upper end” of its guidance, pointing to ...

On February 11, 2026, Biogen announced that Caroline Dorsa, Chair of the company’s Board of Directors, will not stand for re-election at the 2026 Annual Meeting of Stockholders. The company stated ...

Biogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees ...

Analysts, investors and scientists are eager for Biogen’s 2026 BIIB080 readout. Even if successful, executives warn that there are many more steps before the Alzheimer’s therapy could reach the market ...

Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings, with adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer's drug maker reported revenues of ...

The uptick in Leqembi (lecanemab) sales comes a few months after the FDA approved a once-weekly subcutaneous injection ...